IDH1 and acute myeloid leukemia: Targeted therapy using IDH1 and IDH2 inhibitors, including ivosidenib and olutasidenib for IDH1 and enasidenib for IDH2, have been approved for the treatment of AML and are being investigated in MDS [52,53,54].